Paul Shapiro

Dr. Paul Shapiro is a Professor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy, where he leads research on protein kinases and their roles in disease. His work bridges molecular pharmacology, medicinal chemistry, and cancer biology.

Research Interests: Dr. Shapiro’s research focuses on the dysregulation of protein kinases in cancer and inflammatory diseases. His lab specializes in the discovery and development of small-molecule inhibitors targeting ERK1/2 and p38 MAP kinases. By selectively disrupting kinase-substrate interactions using computational and medicinal chemistry techniques, his team aims to improve cancer therapies and reduce off-target toxicity and drug resistance.

Publication Trends: His recent publications (2020–2024) emphasize progress in kinase inhibitors for cancer and respiratory diseases like asthma and COPD. Many of his articles are reviews that synthesize advances in ERK and p38 inhibitor development, highlighting clinical relevance and resistance challenges.

Scientific Awards:

• No awards explicitly mentioned in the source text.

Advising and Grants: While specific students and grant details are not listed, Dr. Shapiro actively mentors researchers in his lab. His work is supported by peer-reviewed publications and collaborative studies, indicating sustained research funding and academic advising in drug discovery and signal transduction.

Labs and Teams: The Shapiro Laboratory develops novel approaches to regulate MAP kinases involved in cancer proliferation and inflammation. The team integrates structural biology, molecular modeling, and cell-based assays to design selective inhibitors, particularly targeting unique docking sites on ERK2 and p38.